Alvine Pharmaceuticals’ ALV003 Named A Top 10 Inflammatory/Autoimmune Project To Watch By Windhover
SAN CARLOS, CA., November 2, 2010 - Alvine Pharmaceuticals, Inc., a leader in celiac disease therapeutics, announced today that the company’s lead therapeutic product candidate, ALV003, has been selected by Windhover and its advisors as one of “The Top 10 Inflammatory/Autoimmune Projects to Watch.” Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology and medical device industries. Alvine has been invited to present at Windhover’s Therapeutic Area Partnerships Conference on November 3, 2010 in Boston, MA.
“We are pleased that ALV003 has been chosen for inclusion on this prestigious list,” said Abhay Joshi, Ph.D., Alvine’s President and Chief Executive Officer. “The selection validates our belief in the potential value of new therapeutics for use in the treatment of celiac disease.”
“Alvine Pharmaceuticals’ ALV003 was selected as one of the Top 10 Projects to Watch by our committee based on rigorous judging criteria. ALV003 is an example of what our committee views to be one of the most attractive inflammatory/autoimmune opportunities in the drug industry,” said David Cassak, VP, Content, Windhover Conferences and Elsevier Business Intelligence. “Each winning selection was hand-picked based on demonstration of high unmet medical need, large market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability.”
Alvine is currently conducting a Phase 2a study of ALV003 in well-controlled celiac disease patients. Details of the study can be found on http://www.clinicaltrials.gov.
ALV003 is an orally administered combination of two recombinant proteases engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues that are common in gluten. ALV003 consists of a glutamine specific cysteine protease (EP-B2) and a proline specific prolyl endopeptidase (PEP). ALV003 is being developed by Alvine as a potential treatment for patients with celiac disease.
About Celiac Disease
Celiac disease is the most common hereditary autoimmune disease with prevalence as high as 1-2% in the U.S. and E.U. Intestinal inflammation in celiac disease is triggered by the ingestion of gluten in genetically susceptible individuals. Gluten is a protein found naturally in wheat, rye, and barley, and is one of the most common and nutritionally significant ingredients in the human diet. Patients with celiac disease mount an immune response to gluten and gluten fragments, resulting in systemic immune mediated damage in the gut and other organs. Gluten ingestion can be associated with symptoms such as nausea, diarrhea, constipation and rash. Complications of celiac disease can include osteoporosis, anemia, dermatitis, weight loss, diabetes, autoimmune diseases, intestinal malignancies, peripheral and central nervous system conditions including depression. The only available option for individuals diagnosed with celiac disease today is a life-long adherence to a strict gluten-free diet, which is difficult to follow.
Alvine Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing therapeutics for autoimmune/gastrointestinal diseases. Alvine’s lead product candidate, ALV003, is being developed as a potential treatment for patients with celiac disease. For additional information about the company, please visit http://www.alvinepharma.com.
Kirk Essenmacher M.D., M.B.A.
Phone: (650) 596-2434
Vice President of Marketing, Corporate and Strategic Development